Robert Miller

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial

A. Marx, S. Muley, R. Conwit, 2019, The Lancet Neurology.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

G. L. Masson, W. Löscher, P. Vermersch, 2017, The Lancet. Neurology.

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial

R. Conwit, D. Schoenfeld, D. Greenblatt, 2014, The Lancet Neurology.

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment

M. Jog, G. Trentin, Farooq Ismail, 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.

Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study

M. Jog, G. Trentin, Farooq Ismail, 2019, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Trials of L-serine in ALS (P3.128)

W. Bradley, D. Forshew, D. Saperstein, 2017 .